These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 17657168

  • 1. Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors.
    Kim CH, Cheon KA, Koo MS, Ryu YH, Lee JD, Chang JW, Lee HS.
    Neuropsychobiology; 2007; 55(3-4):156-62. PubMed ID: 17657168
    [Abstract] [Full Text] [Related]

  • 2. Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder.
    Kim CH, Koo MS, Cheon KA, Ryu YH, Lee JD, Lee HS.
    Eur J Nucl Med Mol Imaging; 2003 Dec; 30(12):1637-43. PubMed ID: 14513291
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder.
    Cheon KA, Ryu YH, Kim YK, Namkoong K, Kim CH, Lee JD.
    Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):306-11. PubMed ID: 12552351
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.
    Humble MB, Uvnäs-Moberg K, Engström I, Bejerot S.
    BMC Psychiatry; 2013 Dec 23; 13():344. PubMed ID: 24359174
    [Abstract] [Full Text] [Related]

  • 11. [Pharmacological treatments for obsessive-compulsive disorder and the serotonin-dopamine hypothesis].
    Okamoto Y.
    Seishin Shinkeigaku Zasshi; 2011 Dec 23; 113(1):36-44. PubMed ID: 21404630
    [Abstract] [Full Text] [Related]

  • 12. Serotonin transporter imaging with [123I]beta-CIT SPECT before and after one year of citalopram treatment of obsessive-compulsive disorder.
    Stengler-Wenzke K, Müller U, Barthel H, Angermeyer MC, Sabri O, Hesse S.
    Neuropsychobiology; 2006 Dec 23; 53(1):40-5. PubMed ID: 16397403
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder.
    Denys D, van der Wee N, Janssen J, De Geus F, Westenberg HG.
    Biol Psychiatry; 2004 May 15; 55(10):1041-5. PubMed ID: 15121489
    [Abstract] [Full Text] [Related]

  • 17. Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): response to escitalopram treatment and basal serotonin transporter (SERT) density.
    Wolmarans de W, Brand L, Stein DJ, Harvey BH.
    Behav Brain Res; 2013 Nov 01; 256():545-53. PubMed ID: 24013013
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Molecular pharmacogenetic studies of drug responses to obsessive-compulsive disorder and six functional genes].
    Zhang L, Liu X, Li T, Yang Y, Hu X, Collier D.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Oct 01; 21(5):479-81. PubMed ID: 15476175
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.